Synopsis:
The board’s approval for a rights issue. With strong Q4FY25 earnings growth and a diverse pharma portfolio, the company continues expanding its footprint across therapeutic segments and dosage forms.
The shares of this Pharmaceutical company gained 5 percent in today’s trading session after the company received Board approval for a rights issue of 13,98,463 fully paid-up equity shares.
With a market capitalization of Rs 704.41 crore, the shares of Kilitch Drugs (India) Ltd were trading at Rs 438.00 per share, increasing around 3.99 percent as compared to the previous closing price of Rs 421.20 apiece.
The shares of Kilitch Drugs (India) Ltd have seen positive movement after the board approved a rights issue of 13,98,463 fully paid-up equity shares at ₹357 each (₹10 face value + ₹347 premium). The record date is July 15, 2025. Shareholders will get 2 rights shares for every 23 shares held. Post-issue, total equity shares will rise to 1,74,80,782, assuming full subscription.
Looking forward to the company’s financial performance, revenue increased by 36 percent from Rs 45 crore in Q4FY24 to Rs 61 crore in Q4FY25. Further, during the same time frame, net profit increased by 150 percent from Rs 4 crore to Rs 10 crore.
Also read: Solar stock jumps after it plans to sell 2.4% stake in its subsidiary via OFS
Kilitch Drugs (India) Ltd offers a diverse pharmaceutical product portfolio including ROIPAR (paracetamol effervescent tablets), ROIVIT (vitamin supplements), and PH-7 (alkalizing sachets). Other key products include CE-certified C-Seal syringes, SRO-ZINC kits for diarrhoea treatment, and 9-VIT multivitamin infusions. These formulations cater to various therapeutic needs, enhancing the company’s presence in the healthcare segment.
Kilitch Drugs (India) Limited is an India-based company that is engaged in the development and operations of the pharmaceutical business. The Company is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s product portfolio includes Parenteral and Nasal Products, Oral, Effervescent, Nutritional Products, Medical Devices, Cosmetics, and Herbal Products.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
